Average common and common equivalent shares - diluted (in thousands)
38,892
38,055
37,500
37,326
37,231
Balance Sheet Data as of June 30:
2019
2018
2017
2016
2015
Cash, cash equivalents and short-term available-for-sale investments
$
166,033
$
181,754
$
157,714
$
95,835
$
110,921
Working capital
310,622
318,856
212,503
199,744
208,515
Total assets
1,884,410
1,593,202
1,558,219
1,129,581
1,063,360
Total shareholders' equity
1,165,589
1,079,061
949,627
879,280
846,935
Cash Flow Data:
2019
2018
2017
2016
2015
Net cash provided by operating activities
181,619
$
170,367
$
143,721
$
144,157
$
139,359
Capital expenditures
25,411
20,934
15,179
16,898
19,905
Cash dividends declared per share
1.28
1.28
1.28
1.28
1.27
Employee Data as of June 30:
2019
2018
2017
2016
2015
Employees
2,255
1,943
1,789
1,560
1,356
(1) (2)
The Company acquired Quad Technologies on July 2, 2018, Exosome Diagnostics on August 1, 2018 and B-Mogen on June 4, 2019. The Company acquired Trevigen on September 5, 2017, Atlanta Biologicals on January 2, 2018, and Eurocell Diagnostics on February 1, 2018.
(3)
The Company acquired Space on July 1, 2016, and Advanced Cell Diagnostics on August 1, 2016.
(4)
The Company acquired Cliniqa on July 8, 2015, and Zephyrus on March 21, 2016.
(5)
The Company acquired Novus Biologicals on July 2, 2014, ProteinSimple on July 31, 2014, and CyVek on November 3, 2014.
(6)
Earnings before income taxes included acquisition related expenses related to amortization of intangibles, costs recognized on sale of acquired inventories and professional fees associated with acquisition activity, as follows: 2019 - $64.9 million; 2018 - $74.2 million; 2017 - $73.2 million; 2016 - $37.6 million; 2015 - $37.6 million.
filings.tools